한글목차

차세대 암 진단의 동향과 예측

세계의 차세대 암 진단 시장은 2024년부터 2030년까지의 복합 연간 성장률(CAGR) 11.0%를 나타낼 전망이며 2030년까지 추정 179억 달러에 이를 것으로 예상됩니다. 이 시장의 주요 촉진요인은 암 질환의 유병률 증가, 효과적인 예후 예측 및 다양한 유형의 암의 조기 발견의 필요성, 그리고 효과적인 진단에 대한 요구 증가에 대응 하기위한 새로운 접근법의 창출을 향한 중요한 이해 관계자의 노력 증가입니다. 바이오마커 개발, CTC 해석, 프로테옴 해석, 후성 유전 해석, 유전자 분석의 각 시장에 있어서의 기회에 의해 세계의 차세대 암 진단 시장의 미래는 유망시되고 있습니다.

차세대 암 진단 시장 인사이트

Lucintel은 암치료에 있어서의 면역요법이나 표적치료의 보급에 의해 효율적인 치료모니터링 수요가 높아지고 있기 때문에 예측기간 동안에도 치료모니터링이 최대부문인 것으로 예측했습니다.

북미는 견고한 헬스케어 시스템의 존재와 암 연구에 강한 주력을 하고 있기 때문에 예측기간 중에도 최대의 지역으로 계속 될 것으로 보입니다.

FAQ

Q1. 시장 규모는?

A1. 세계의 차세대 암 진단 시장은 2030년까지 추정 179억 달러까지 도달할 것으로 예상됩니다.

Q2. 시장의 성장 예측은?

A2. 차세대 암 진단 시장은 2024년부터 2030년에 걸쳐 복합 연간 성장률(CAGR) 11.0%로 성장할 것으로 예측됩니다.

Q3. 시장 성장에 영향을 미치는 주요 촉진요인은?

A3.이 시장의 주요 촉진요인은 암 질환의 유병률 증가, 효과적인 예후 예측 및 다양한 유형의 암의 조기 발견의 필요성, 또한 효과적인 진단에 대한 요구 증가 에 대응하기 위한 새로운 접근법을 창출하기 위한 중요한 이해관계자의 노력 증가입니다.

Q4. 시장의 주요 부문은?

A4. 바이오마커 개발, CTC 해석, 프로테옴 해석, 후성 유전 해석, 유전자 분석의 각 시장에 있어서의 기회에 의해 세계의 차세대 암 진단 시장의 미래는 유망합니다.

Q5. 시장의 주요 기업은?

A5. 차세대 암 진단 주요 기업은 다음과 같습니다.

• Janssen Pharmaceuticals
• Illumina
• Novartis
• F. Hoffmann-La Roche
• Koninklijke Philips
• QIAGEN
• Agilent Technologies
• Abbott
• Thermo Fisher Scientific
• GE HealthCare

Q6. 앞으로 가장 큰 시장 부문은?

A6. Lucintel은 암 치료에 있어서의 면역요법이나 표적 치료의 보급에 의해 효율적인 치료 모니터링 수요가 높아지고 있기 때문에 예측 기간 동안에도 치료 모니터링이 최대 부문으로 계속될 것으로 예측했습니다.

Q7. 시장에서 향후 5년간 최대가 될 것으로 예상되는 지역은?

A7. 북미는 견고한 헬스케어 시스템의 존재와 암 연구에 강한 주력을 하고 있기 때문에 예측기간 중에도 최대의 지역으로 계속 될 것으로 보입니다.

Q8. 보고서의 커스터마이즈는 가능?

A8. 그렇습니다, Lucintel는 추가 비용 없이 10% 주문을 받아서 만듭니다.

목차

제1장 주요 요약

제2장 세계의 차세대 암 진단 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018년-2023년)과 예측(2024년-2030년)
• 세계의 차세대 암 진단 시장 동향(2018년-2023년)과 예측(2024년-2030년)
• 암 유형별 세계의 차세대 암 진단 시장
  • 폐암
  • 유방암
  • 결장직장암
  • 자궁경부암
  • 기타
• 기술별 세계의 차세대 암 진단 시장
  • 차세대 시퀀싱
  • 정량 PCR과 다중
  • 실험실 온칩과 역전사 PCR
  • 단백질 마이크로어레이
  • DNA 마이크로어레이
• 기능별 세계의 차세대 암 진단 시장
  • 치료 모니터링
  • 동반진단
  • 예후
  • 암 검진
  • 리스크 분석
• 용도별 세계의 차세대 암 진단 시장
  • 바이오마커 개발
  • CTC 분석
  • 프로테옴 해석
  • 후성 유전 분석
  • 유전자 분석
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018년-2023년)

• 지역별 세계의 차세대 암 진단 시장
• 북미의 차세대 암 진단 시장
• 유럽의 차세대 암 진단 시장
• 아시아태평양의 차세대 암 진단 시장
• 기타 지역의 차세대 암 진단 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상의 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 암유형별 세계의 차세대 암 진단 시장의 성장 기회
  • 기술별 세계의 차세대 암 진단 시장의 성장 기회
  • 기능별 세계의 차세대 암 진단 시장의 성장 기회
  • 용도별 세계의 차세대 암 진단 시장의 성장 기회
  • 지역별 세계의 차세대 암 진단 시장의 성장 기회
• 세계의 차세대 암 진단 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 차세대 암 진단 시장의 능력 확대
  • 세계의 차세대 암 진단 시장에서의 합병, 인수, 합작 사업
  • 인증 및 라이선싱

제7장 유력 기업의 기업 프로파일

• Janssen Pharmaceuticals
• Illumina
• Novartis
• F. Hoffmann-La Roche
• Koninklijke Philips
• QIAGEN
• Agilent Technologies
• Abbott
• Thermo Fisher Scientific
• GE HealthCare

영문목차

Next Generation Cancer Diagnostics Trends and Forecast

The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets. The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.

A more than 150-page report is developed to help in your business decisions.

Next Generation Cancer Diagnostics by Segment

The study includes a forecast for the global next generation cancer diagnostics by cancer type, technology, function, application, and region.

Next Generation Cancer Diagnostics Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Others

Next Generation Cancer Diagnostics Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

• Next-Generation Sequencing
• qPCR & Multiplexing
• Lab-On-A-Chip & Reverse Transcriptase-PCR
• Protein Microarrays
• DNA Microarrays

Next Generation Cancer Diagnostics Market by Function [Shipment Analysis by Value from 2018 to 2030]:

• Therapeutic Monitoring
• Companion Diagnostics
• Prognostics
• Cancer Screening
• Risk Analysis

Next Generation Cancer Diagnostics Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis
• Others

Next Generation Cancer Diagnostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Next Generation Cancer Diagnostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies next generation cancer diagnostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the next generation cancer diagnostics companies profiled in this report include-

• Janssen Pharmaceuticals
• Illumina
• Novartis
• F. Hoffmann-La Roche
• Koninklijke Philips
• QIAGEN
• Agilent Technologies
• Abbott
• Thermo Fisher Scientific
• GE HealthCare

Next Generation Cancer Diagnostics Market Insights

Lucintel forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.

North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.

Features of the Global Next Generation Cancer Diagnostics Market

Market Size Estimates: Next generation cancer diagnostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Next generation cancer diagnostics market size by various segments, such as by cancer type, technology, function, application, and region in terms of value ($B).

Regional Analysis: Next generation cancer diagnostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer type, technology, function, application, and regions for the next generation cancer diagnostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the next generation cancer diagnostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the next generation cancer diagnostics market size?

Answer: The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030.

Q2. What is the growth forecast for next generation cancer diagnostics market?

Answer: The global next generation cancer diagnostics market is expected to grow with a CAGR of 11.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the next generation cancer diagnostics market?

Answer: The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.

Q4. What are the major segments for next generation cancer diagnostics market?

Answer: The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets.

Q5. Who are the key next generation cancer diagnostics market companies?

Answer: Some of the key next generation cancer diagnostics companies are as follows.

• Janssen Pharmaceuticals
• Illumina
• Novartis
• F. Hoffmann-La Roche
• Koninklijke Philips
• QIAGEN
• Agilent Technologies
• Abbott
• Thermo Fisher Scientific
• GE HealthCare

Q6. Which next generation cancer diagnostics market segment will be the largest in future?

Answer: Lucintel forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.

Q7. In next generation cancer diagnostics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the next generation cancer diagnostics market by cancer type (lung cancer, breast cancer, colorectal cancer, cervical cancer, and others), technology (next-generation sequencing, qPCR & multiplexing, lab-on-a-chip & reverse transcriptase-PCR , protein microarrays, and DNA microarrays), function (therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis), application (biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, genetic analysis, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Next Generation Cancer Diagnostics Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Next Generation Cancer Diagnostics Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Next Generation Cancer Diagnostics Market by Cancer Type
  • 3.3.1: Lung Cancer
  • 3.3.2: Breast Cancer
  • 3.3.3: Colorectal Cancer
  • 3.3.4: Cervical Cancer
  • 3.3.5: Others
• 3.4: Global Next Generation Cancer Diagnostics Market by Technology
  • 3.4.1: Next-generation Sequencing
  • 3.4.2: qPCR & Multiplexing
  • 3.4.3: Lab-on-a-chip & Reverse Transcriptase-PCR
  • 3.4.4: Protein Microarrays
  • 3.4.5: DNA Microarrays
• 3.5: Global Next Generation Cancer Diagnostics Market by Function
  • 3.5.1: Therapeutic Monitoring
  • 3.5.2: Companion Diagnostics
  • 3.5.3: Prognostics
  • 3.5.4: Cancer Screening
  • 3.5.5: Risk Analysis
• 3.6: Global Next Generation Cancer Diagnostics Market by Application
  • 3.6.1: Biomarker Development
  • 3.6.2: CTC Analysis
  • 3.6.3: Proteomic Analysis
  • 3.6.4: Epigenetic Analysis
  • 3.6.5: Genetic Analysis
  • 3.6.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Next Generation Cancer Diagnostics Market by Region
• 4.2: North American Next Generation Cancer Diagnostics Market
  • 4.2.1: North American Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
  • 4.2.2: North American Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
• 4.3: European Next Generation Cancer Diagnostics Market
  • 4.3.1: European Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
  • 4.3.2: European Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
• 4.4: APAC Next Generation Cancer Diagnostics Market
  • 4.4.1: APAC Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
  • 4.4.2: APAC Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others
• 4.5: ROW Next Generation Cancer Diagnostics Market
  • 4.5.1: ROW Next Generation Cancer Diagnostics Market by Function: Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, and Risk Analysis
  • 4.5.2: ROW Next Generation Cancer Diagnostics Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Cancer Type
  • 6.1.2: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Technology
  • 6.1.3: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Function
  • 6.1.4: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Application
  • 6.1.5: Growth Opportunities for the Global Next Generation Cancer Diagnostics Market by Region
• 6.2: Emerging Trends in the Global Next Generation Cancer Diagnostics Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Next Generation Cancer Diagnostics Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Next Generation Cancer Diagnostics Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Janssen Pharmaceuticals
• 7.2: Illumina
• 7.3: Novartis
• 7.4: F. Hoffmann-La Roche
• 7.5: Koninklijke Philips
• 7.6: QIAGEN
• 7.7: Agilent Technologies
• 7.8: Abbott
• 7.9: Thermo Fisher Scientific
• 7.10: GE HealthCare